Krystal Biotech (KRYS)

Krystal’s lead commercial product is VYJUVEK, a redosable topical gene therapy for dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen. The medicine delivers functional COL7A1 genes directly to wounds, aiming to promote production of the collagen needed for stronger skin anchoring. The company manufactures, markets, and sells VYJUVEK in the United States and also markets the therapy in other approved regions, including the European Union and Japan.

The business is vertically integrated, combining research, clinical development, manufacturing, regulatory, and commercial capabilities. That structure gives Krystal greater control over production quality and supply, which are critical in gene therapy because products can be technically complex and tightly regulated. Beyond its marketed therapy, the company applies its platform to additional genetic medicine programs across areas such as dermatology and other serious disorders.

Krystal Biotech stands out among biotechnology companies because it has moved from platform development into commercial execution. Its performance is tied to adoption of VYJUVEK, reimbursement access, manufacturing reliability, and the company’s ability to extend its HSV-1 gene delivery technology into broader therapeutic opportunities.